Immunotherapy: bewitched, bothered, and bewildered no more
about
The response of autologous T cells to a human melanoma is dominated by mutated neoantigensThe significance of glucose, insulin and potassium for immunology and oncology: a new model of immunity.Sperm protein 17 is expressed in human nervous system tumours.Why primate models matter.A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy.Decreased activation of inflammatory networks during acute asthma exacerbations is associated with chronic airflow obstruction.A prescription for human immunology.Immunological treatment options for locoregionally advanced head and neck squamous cell carcinomaT cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.Utility of Clostridium difficile toxin B for inducing anti-tumor immunity.Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab.Dendritic cells as therapeutic vaccines against cancer.Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and CancerHLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinomaExtracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade.T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.Immunological treatment of liver tumorsCaspase-dependent immunogenicity of doxorubicin-induced tumor cell death.Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles.Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.Human immune system variationFrom vaccines to memory and back.Induction of immune tolerance in the treatment of rheumatoid arthritis.Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine.Combining immunotherapy and targeted therapies in cancer treatment.Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer ImmunityEffect of oxygen levels on the physiology of dendritic cells: implications for adoptive cell therapy.Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.Cancer immunotherapy: are we there yet?Cancer immunotherapy.Understanding and activating immunity against human cancer.Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.Research on human subjects in the JEM.IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.Epigenome: the program for human health and disease.
P2860
Q24535034-BC7ECE5F-44CD-4058-A75F-C4987AD29CD7Q24812411-3D06886E-9FD2-47E1-9CEA-64934C7A2A7CQ25256674-0BB45725-82BA-474C-BB4C-5613B3809E09Q30417520-F0BE5EB7-A10E-4D4A-A215-BA487B5D3629Q33299767-D21A66CD-6CE3-4BB2-8FA8-DBE6E4E39902Q33937638-C216C6C0-C4EF-41E2-AF37-0A92CDB6E546Q34001827-F30A5513-5C22-4F24-AC5F-A79551FCCD14Q34181954-9ADB49D8-CA14-46AB-85DA-FB7A822C69DBQ34343664-27040F09-371F-40B3-828A-0F0A3CFB2AB4Q34395494-C1B6AD9C-7AF9-46D0-9781-BCE5C07BF355Q35506684-47C4CFD2-9EB0-43EC-9978-7BA91A62381BQ36085614-3291B69F-5CB3-4F99-9457-8FBD6F7E8CBCQ36127825-2B1E5AC5-2442-4050-B985-F8160B92BFC5Q36184723-C84EF048-7E92-4C91-9202-55C1FAD5C60EQ36259431-B1614469-591D-425C-9B2F-5B62AD4052ECQ36297606-B1CBB805-A0E4-4FA1-8F00-9D168D0951B6Q36373254-653675DB-2F24-492E-A8AD-38C3FD11B356Q36403093-86B8720E-C62B-4C70-A535-690DC6596413Q36471831-7FC4824E-575C-4250-9A29-9B7CF2FA58A4Q36611772-5241318C-2E52-4298-9C7B-9094E3142CFDQ36715205-4356D73D-679D-42A1-8387-0CBA04CF20D2Q37040202-EBD2F3F1-EEE7-4994-A5BC-874D551C6012Q37308037-5759FCF3-F4E7-44D9-B623-31B72C760711Q37395354-346E0611-850D-4F48-9990-DE771177E842Q37669442-8BF72272-E109-456D-93C9-944BACC65567Q37804530-5E2ACCDC-564B-46DC-95E2-78A319A5EB49Q37862081-108AC6AC-B660-499C-A7BF-66D21BF98768Q37971324-C7CBE9EF-2EAB-4661-A6F7-B6B56F250E43Q37995939-89D1EF1F-5304-458B-BBD3-490680B9FC98Q38174601-E5BAF288-FC53-4175-AAFF-0249FA32B75AQ38649472-9B6DD2F6-F8C7-4C7C-A0FA-928FAD48B786Q38659916-E437A1F8-9715-4B63-9279-6F3E4464648BQ39297560-16A30DE2-7EF0-4FC0-9500-232AA08236CAQ39958332-4C09770C-E5C6-4952-BCD3-2971941803AAQ40297410-0037A238-E749-4735-91FE-9B0B8C310D6DQ41849280-2900A9AC-6E77-439C-9675-7FC3A00C28A3Q42288627-9C6B33E8-62EA-486C-8815-4FA00CE70836Q42972481-DEFCCB78-1EDE-4287-AD86-3324A559EF77Q50892802-9EEFFF61-A1F7-49E8-8117-C8742A3BF80CQ52618838-BC85805E-AE7D-49F4-9B17-CB515C7291EA
P2860
Immunotherapy: bewitched, bothered, and bewildered no more
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Immunotherapy: bewitched, bothered, and bewildered no more
@ast
Immunotherapy: bewitched, bothered, and bewildered no more
@en
Immunotherapy: bewitched, bothered, and bewildered no more
@nl
type
label
Immunotherapy: bewitched, bothered, and bewildered no more
@ast
Immunotherapy: bewitched, bothered, and bewildered no more
@en
Immunotherapy: bewitched, bothered, and bewildered no more
@nl
prefLabel
Immunotherapy: bewitched, bothered, and bewildered no more
@ast
Immunotherapy: bewitched, bothered, and bewildered no more
@en
Immunotherapy: bewitched, bothered, and bewildered no more
@nl
P356
P1433
P1476
Immunotherapy: bewitched, bothered, and bewildered no more
@en
P2093
Ira Mellman
Ralph M Steinman
P304
P356
10.1126/SCIENCE.1099688
P407
P577
2004-07-09T00:00:00Z